Fig. 1From: Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016–2017 epidemic season: a systematic review of seven Italian reportsPatient percentage distribution across 3 epidemic seasons for premature with and without comorbidities and not premature infants with comorbiditiesBack to article page